Kan, The 10K that will be filed will only show up to Dec. 31, 2005; it is called an Annual Report and the only new information will be what occurred during the 4th quarter of 2005. Therefore, the 10K will show us how many shares were sold through PPO's, if any, and at what price to pay for the $2 Million synDNA prototype, rent, lawyers, salaries, etc. These numbers could effect the stock price positively or negatively depending on what is shown. It may depend on how many total outstanding shares it shows.
An 8K will be filed approx. mid-May; that will be the first quarter report for 2006. This report should show any revenue received from Aldveron, if it was received prior to Mar. 31, 2006. The 8K hopefully could have a very postive effect on the share price if CYGX can finally report revenue from one of it's products.
"If the facts don't fit the theory, change the facts."
